Chardan Capital Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $22

Benzinga · 04/08/2025 10:49
Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and lowers the price target from $25 to $22.